Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GKOS Stock Forecast 2025-2026
$97.19
Current Price
$5.45B
Market Cap
Buy 12
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to GKOS Price Targets
+69.8%
To High Target of $165.00
+18.3%
To Median Target of $115.00
-25.9%
To Low Target of $72.00
GKOS Price Momentum
+1.8%
1 Week Change
+1.8%
1 Month Change
-10.7%
1 Year Change
-35.2%
Year-to-Date Change
-40.6%
From 52W High of $163.71
+26.1%
From 52W Low of $77.10
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Glaukos (GKOS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on GKOS and similar high-potential opportunities.
Latest GKOS Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, GKOS has a bullish consensus with a median price target of $115.00 (ranging from $72.00 to $165.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $97.19, the median forecast implies a 18.3% upside. This outlook is supported by 12 Buy, 2 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Matt O'Brien at Piper Sandler, projecting a 69.8% upside. Conversely, the most conservative target is provided by Patrick Wood at Morgan Stanley, suggesting a 25.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GKOS Analyst Ratings
12
Buy
2
Hold
1
Sell
GKOS Price Target Range
Low
$72.00
Average
$115.00
High
$165.00
Current: $97.19
Latest GKOS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GKOS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2025 | Morgan Stanley | Patrick Wood | Underweight | Maintains | $72.00 |
| May 2, 2025 | Stephens & Co. | Mason Carrico | Overweight | Maintains | $115.00 |
| May 1, 2025 | Stifel | Thomas Stephan | Buy | Maintains | $115.00 |
| May 1, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Downgrade | $86.00 |
| May 1, 2025 | Truist Securities | Richard Newitter | Buy | Reiterates | $135.00 |
| May 1, 2025 | Needham | David Saxon | Buy | Maintains | $115.00 |
| Apr 16, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $175.00 |
| Apr 15, 2025 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $165.00 |
| Apr 11, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $140.00 |
| Feb 21, 2025 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $160.00 |
| Feb 21, 2025 | Needham | David Saxon | Buy | Maintains | $176.00 |
| Feb 19, 2025 | Mizuho | Anthony Petrone | Outperform | Upgrade | $200.00 |
| Jan 27, 2025 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $180.00 |
| Dec 31, 2024 | Stifel | Thomas Stephan | Buy | Maintains | $175.00 |
| Dec 18, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $185.00 |
| Dec 11, 2024 | Citigroup | Joanne Wuensch | Buy | Upgrade | $162.00 |
| Dec 11, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $153.00 |
| Dec 6, 2024 | UBS | Danielle Antalffy | Buy | Initiates | $182.00 |
| Dec 2, 2024 | Stifel | Thomas Stephan | Buy | Maintains | $153.00 |
| Dec 2, 2024 | Morgan Stanley | Patrick Wood | Underweight | Downgrade | $120.00 |
Glaukos Corporation (GKOS) Competitors
The following stocks are similar to Glaukos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Glaukos Corporation (GKOS) Financial Data
Glaukos Corporation has a market capitalization of $5.45B with a P/E ratio of -34.5x. The company generates $404.52M in trailing twelve-month revenue with a -30.6% profit margin.
Revenue growth is +24.6% quarter-over-quarter, while maintaining an operating margin of -19.4% and return on equity of -20.4%.
Valuation Metrics
Market Cap
$5.45B
Enterprise Value
$5.22B
P/E Ratio
-34.5x
PEG Ratio
-86.7x
Price/Sales
13.5x
Growth & Margins
Revenue Growth (YoY)
+24.6%
Gross Margin
+77.2%
Operating Margin
-19.4%
Net Margin
-30.6%
EPS Growth
+24.6%
Financial Health
Cash/Price Ratio
+5.4%
Current Ratio
6.5x
Debt/Equity
14.1x
ROE
-20.4%
ROA
-6.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Glaukos Corporation (GKOS) Business Model
About Glaukos Corporation
What They Do
Develops innovative glaucoma treatment technologies.
Business Model
Glaukos Corporation generates revenue by developing and commercializing advanced medical devices specifically for treating glaucoma and other ophthalmic conditions. The company focuses on micro-invasive surgical techniques, providing alternatives to traditional treatments, which allows them to tap into a significant market of patients seeking less invasive options.
Additional Information
The company is recognized for its pioneering work in micro-invasive glaucoma surgery (MIGS), addressing the urgent needs in ophthalmic healthcare. By improving patient outcomes and quality of life, Glaukos plays a critical role in the healthcare industry, particularly in combating glaucoma, a leading cause of irreversible blindness worldwide.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
995
CEO
Mr. Thomas William Burns
Country
United States
IPO Year
2015
Website
www.glaukos.comGlaukos Corporation (GKOS) Latest News & Analysis
Latest News
Quick Summary
GKOS reports strong product demand and market expansion, supported by a promising development pipeline, indicating positive growth prospects for investors.
Why It Matters
GKOS's strong product demand and market expansion indicate potential revenue growth. A robust development pipeline suggests future profitability, making it an attractive investment opportunity.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Glaukos Corporation (NYSE: GKOS) will participate in the Stifel 2025 Virtual Ophthalmology Forum on May 27, 2025, and the William Blair 45th Annual Growth Stock Conference on June 3, 2025.
Why It Matters
Glaukos Corporation's participation in key investor conferences highlights its commitment to engaging with the investment community, potentially influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Glaukos Corporation (NYSE:GKOS) will hold its Q1 2025 Earnings Conference Call on April 30, 2025, at 4:30 PM ET with key executives and analysts participating.
Why It Matters
The upcoming earnings call provides insights into Glaukos Corporation's financial health and future prospects, influencing investor sentiment and potential stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Glaukos Corporation reported Q1 2025 net sales of $106.7 million, a 25% year-over-year increase. This growth reflects strong performance in glaucoma treatment and related therapies.
Why It Matters
Glaukos Corporation's record sales growth indicates strong demand for its products, potentially boosting investor confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Glaukos (GKOS) reported a quarterly loss of $0.22 per share, better than the expected loss of $0.33, and improved from a loss of $0.70 per share a year prior.
Why It Matters
Glaukos' smaller-than-expected loss indicates improved financial performance, potentially boosting investor confidence and affecting stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Glaukos reported a significant increase in revenues for Q1, but still faced ongoing operating losses, which could impact investor sentiment.
Why It Matters
Glaukos' revenue growth signals potential market confidence, but ongoing operating losses may indicate financial instability, affecting future profitability and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About GKOS Stock
What is Glaukos Corporation's (GKOS) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, Glaukos Corporation (GKOS) has a median price target of $115.00. The highest price target is $165.00 and the lowest is $72.00.
Is GKOS stock a good investment in 2025?
According to current analyst ratings, GKOS has 12 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $97.19. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GKOS stock?
Wall Street analysts predict GKOS stock could reach $115.00 in the next 12 months. This represents a 18.3% increase from the current price of $97.19. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Glaukos Corporation's business model?
Glaukos Corporation generates revenue by developing and commercializing advanced medical devices specifically for treating glaucoma and other ophthalmic conditions. The company focuses on micro-invasive surgical techniques, providing alternatives to traditional treatments, which allows them to tap into a significant market of patients seeking less invasive options.
What is the highest forecasted price for GKOS Glaukos Corporation?
The highest price target for GKOS is $165.00 from Matt O'Brien at Piper Sandler, which represents a 69.8% increase from the current price of $97.19.
What is the lowest forecasted price for GKOS Glaukos Corporation?
The lowest price target for GKOS is $72.00 from Patrick Wood at Morgan Stanley, which represents a -25.9% decrease from the current price of $97.19.
What is the overall GKOS consensus from analysts for Glaukos Corporation?
The overall analyst consensus for GKOS is bullish. Out of 20 Wall Street analysts, 12 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $115.00.
How accurate are GKOS stock price projections?
Stock price projections, including those for Glaukos Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 4:15 PM UTC